Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 433

1.

Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5.

Fizazi K, Jones R, Oudard S, Efstathiou E, Saad F, de Wit R, De Bono J, Cruz FM, Fountzilas G, Ulys A, Carcano F, Agarwal N, Agus D, Bellmunt J, Petrylak DP, Lee SY, Webb IJ, Tejura B, Borgstein N, Dreicer R.

J Clin Oncol. 2015 Jan 26. pii: JCO.2014.56.5119. [Epub ahead of print]

PMID:
25624429
[PubMed - as supplied by publisher]
2.

Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer.

Koutras A, Kotoula V, Fountzilas G.

Pharmacogenomics. 2015 Jan;16(1):79-94. doi: 10.2217/pgs.14.148.

PMID:
25560472
[PubMed - in process]
3.

Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer.

Kourlaba G, Dimopoulos MA, Pectasides D, Skarlos DV, Gogas H, Pentheroudakis G, Koutras A, Fountzilas G, Maniadakis N.

Support Care Cancer. 2014 Dec 19. [Epub ahead of print]

PMID:
25524005
[PubMed - as supplied by publisher]
4.

Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer.

Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA.

J Clin Oncol. 2014 Dec 1. pii: JCO.2014.57.1414. [Epub ahead of print]

PMID:
25452441
[PubMed - as supplied by publisher]
5.

Protein and mRNA expression of notch pathway components in operable tumors of patients with laryngeal cancer.

Krikelis D, Kotoula V, Bobos M, Fountzilas E, Markou K, Karasmanis I, Angouridakis N, Vlachtsis K, Kalogeras KT, Nikolaou A, Fountzilas G.

Anticancer Res. 2014 Nov;34(11):6495-503.

PMID:
25368251
[PubMed - indexed for MEDLINE]
6.

Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology Group.

Karavasilis V, Kosmidis P, Syrigos KN, Mavropoulou P, Dimopoulos MA, Kotoula V, Pectasides D, Boukovinas I, Klouvas G, Kalogera-Fountzila A, Papandreou CN, Fountzilas G, Briasoulis E.

Anticancer Res. 2014 Oct;34(10):5649-55.

PMID:
25275069
[PubMed - indexed for MEDLINE]
7.

Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.

Koumarianou A, Tzeveleki I, Mekras D, Eleftheraki AG, Bobos M, Wirtz R, Fountzilas E, Valavanis C, Xanthakis I, Kalogeras KT, Basdanis G, Pentheroudakis G, Kotoula V, Fountzilas G.

Anticancer Res. 2014 Sep;34(9):4949-62.

PMID:
25202077
[PubMed - indexed for MEDLINE]
8.

Intact or broken-apart RNA: an alternative concept for ALK fusion screening in non-small cell lung cancer (NSCLC).

Kotoula V, Bobos M, Vassilakopoulou M, Tsolaki E, Chrisafi S, Psyrri A, Lazaridis G, Papadopoulou K, Efstratiou I, Michail-Strantzia C, Debelenko LV, Kosmidis P, Fountzilas G.

Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):60-70. doi: 10.1097/PAI.0000000000000028.

PMID:
25153496
[PubMed - in process]
9.

EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial.

Cheng H, Ballman K, Vassilakopoulou M, Dueck AC, Reinholz MM, Tenner K, Gralow J, Hudis C, Davidson NE, Fountzilas G, McCullough AE, Chen B, Psyrri A, Rimm DL, Perez EA.

Br J Cancer. 2014 Sep 9;111(6):1065-71. doi: 10.1038/bjc.2014.442. Epub 2014 Aug 12.

PMID:
25117817
[PubMed - indexed for MEDLINE]
10.

Adjusting breast cancer patient prognosis with non-HER2-gene patterns on chromosome 17.

Kotoula V, Bobos M, Alexopoulou Z, Papadimitriou C, Papadopoulou K, Charalambous E, Tsolaki E, Xepapadakis G, Nicolaou I, Papaspirou I, Aravantinos G, Christodoulou C, Efstratiou I, Gogas H, Fountzilas G.

PLoS One. 2014 Aug 6;9(8):e103707. doi: 10.1371/journal.pone.0103707. eCollection 2014.

PMID:
25098819
[PubMed - in process]
Free PMC Article
11.

p85 Protein Expression is Associated with Poor Survival in HER2-Positive Patients with Advanced Breast Cancer Treated with Trastuzumab.

Pavlakis K, Bobos M, Batistatou A, Kotoula V, Eleftheraki AG, Stofas A, Timotheadou E, Pentheroudakis G, Psyrri A, Koutras A, Pectasides D, Papakostas P, Razis E, Christodoulou C, Kalogeras KT, Fountzilas G.

Pathol Oncol Res. 2014 Aug 8. [Epub ahead of print]

PMID:
25098276
[PubMed - as supplied by publisher]
12.

The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system.

Dermitzakis EV, Kimiskidis VK, Eleftheraki A, Lazaridis G, Konstantis A, Basdanis G, Tsiptsios I, Georgiadis G, Fountzilas G.

Eur J Neurol. 2014 Dec;21(12):1471-7. doi: 10.1111/ene.12514. Epub 2014 Jul 17.

PMID:
25041285
[PubMed - in process]
13.

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial.

Fountzilas G, Dafni U, Papadimitriou C, Timotheadou E, Gogas H, Eleftheraki AG, Xanthakis I, Christodoulou C, Koutras A, Papandreou CN, Papakostas P, Miliaras S, Markopoulos C, Dimitrakakis C, Korantzopoulos P, Karanikiotis C, Bafaloukos D, Kosmidis P, Samantas E, Varthalitis I, Pavlidis N, Pectasides D, Dimopoulos MA.

BMC Cancer. 2014 Jul 15;14:515. doi: 10.1186/1471-2407-14-515.

PMID:
25026897
[PubMed - in process]
Free PMC Article
14.

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

Geva R, Vecchione L, Kalogeras KT, Vittrup Jensen B, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.

Gut. 2014 Jul 10. pii: gutjnl-2014-307234. doi: 10.1136/gutjnl-2014-307234. [Epub ahead of print]

PMID:
25011934
[PubMed - as supplied by publisher]
15.

Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.

Pentheroudakis G, Kotteas EA, Kotoula V, Papadopoulou K, Charalambous E, Cervantes A, Ciuleanu T, Fountzilas G, Pavlidis N.

Clin Exp Metastasis. 2014 Oct;31(7):761-9. doi: 10.1007/s10585-014-9666-1. Epub 2014 Jul 5.

PMID:
24997156
[PubMed - indexed for MEDLINE]
16.

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies.

Koletsa T, Stavridi F, Bobos M, Kostopoulos I, Kotoula V, Eleftheraki AG, Konstantopoulou I, Papadimitriou C, Batistatou A, Gogas H, Koutras A, Skarlos DV, Pentheroudakis G, Efstratiou I, Pectasides D, Fountzilas G.

BMC Clin Pathol. 2014 Jun 23;14:28. doi: 10.1186/1472-6890-14-28. eCollection 2014.

PMID:
24987308
[PubMed]
Free PMC Article
17.

In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.

Vassilakopoulou M, Togun T, Dafni U, Cheng H, Bordeaux J, Neumeister VM, Bobos M, Pentheroudakis G, Skarlos DV, Pectasides D, Kotoula V, Fountzilas G, Rimm DL, Psyrri A.

PLoS One. 2014 Jun 26;9(6):e99131. doi: 10.1371/journal.pone.0099131. eCollection 2014.

PMID:
24968015
[PubMed - in process]
Free PMC Article
18.

Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade.

Purrington KS, Slettedahl S, Bolla MK, Michailidou K, Czene K, Nevanlinna H, Bojesen SE, Andrulis IL, Cox A, Hall P, Carpenter J, Yannoukakos D, Haiman CA, Fasching PA, Mannermaa A, Winqvist R, Brenner H, Lindblom A, Chenevix-Trench G, Benitez J, Swerdlow A, Kristensen V, Guénel P, Meindl A, Darabi H, Eriksson M, Fagerholm R, Aittomäki K, Blomqvist C, Nordestgaard BG, Nielsen SF, Flyger H, Wang X, Olswold C, Olson JE, Mulligan AM, Knight JA, Tchatchou S, Reed MW, Cross SS, Liu J, Li J, Humphreys K, Clarke C, Scott R; ABCTB Investigators, Fostira F, Fountzilas G, Konstantopoulou I, Henderson BE, Schumacher F, Le Marchand L, Ekici AB, Hartmann A, Beckmann MW, Hartikainen JM, Kosma VM, Kataja V, Jukkola-Vuorinen A, Pylkäs K, Kauppila S, Dieffenbach AK, Stegmaier C, Arndt V, Margolin S; Australian Ovarian Cancer Study Group; kConFab Investigators, Balleine R, Arias Perez JI, Pilar Zamora M, Menéndez P, Ashworth A, Jones M, Orr N, Arveux P, Kerbrat P, Truong T, Bugert P, Toland AE, Ambrosone CB, Labrèche F, Goldberg MS, Dumont M, Ziogas A, Lee E, Dite GS, Apicella C, Southey MC, Long J, Shrubsole M, Deming-Halverson S, Ficarazzi F, Barile M, Peterlongo P, Durda K, Jaworska-Bieniek K, Tollenaar RA, Seynaeve C; GENICA Network, Brüning T, Ko YD, Van Deurzen CH, Martens JW, Kriege M, Figueroa JD, Chanock SJ, Lissowska J, Tomlinson I, Kerin MJ, Miller N, Schneeweiss A, Tapper WJ, Gerty SM, Durcan L, Mclean C, Milne RL, Baglietto L, dos Santos Silva I, Fletcher O, Johnson N, Van'T Veer LJ, Cornelissen S, Försti A, Torres D, Rüdiger T, Rudolph A, Flesch-Janys D, Nickels S, Weltens C, Floris G, Moisse M, Dennis J, Wang Q, Dunning AM, Shah M, Brown J, Simard J, Anton-Culver H, Neuhausen SL, Hopper JL, Bogdanova N, Dörk T, Zheng W, Radice P, Jakubowska A, Lubinski J, Devillee P, Brauch H, Hooning M, García-Closas M, Sawyer E, Burwinkel B, Marmee F, Eccles DM, Giles GG, Peto J, Schmidt M, Broeks A, Hamann U, Chang-Claude J, Lambrechts D, Pharoah PD, Easton D, Pankratz VS, Slager S, Vachon CM, Couch FJ.

Hum Mol Genet. 2014 Nov 15;23(22):6034-46. doi: 10.1093/hmg/ddu300. Epub 2014 Jun 13.

PMID:
24927736
[PubMed - in process]
19.

Lack of association between KRAS mutations and 18F-FDG PET/CT in Caucasian metastatic colorectal cancer patients.

Krikelis D, Skoura E, Kotoula V, Rondogianni P, Pianou N, Samartzis A, Xanthakis I, Fountzilas G, Datseris IE.

Anticancer Res. 2014 May;34(5):2571-9.

PMID:
24778079
[PubMed - indexed for MEDLINE]
20.

Markers of epithelial to mesenchymal transition in association with survival in head and neck squamous cell carcinoma (HNSCC).

Pectasides E, Rampias T, Sasaki C, Perisanidis C, Kouloulias V, Burtness B, Zaramboukas T, Rimm D, Fountzilas G, Psyrri A.

PLoS One. 2014 Apr 10;9(4):e94273. doi: 10.1371/journal.pone.0094273. eCollection 2014.

PMID:
24722213
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk